Abstract：
OBJECTIVE: Mirogabalin is a novel gabapentinoid medication for the treatment of neuropathic pain. The purpose of this review is to discuss current evidence for its use. Gabapentinoids are widely prescribed for neuropathic pain. Mirogabalin offers theoretical advantages over traditional gabapentinoids due to its specificity for the α2δ-1 subunit of voltage-gated calcium channels. It is theorised that this specificity may reduce adverse drug reactions by minimising binding to the α2δ-2 subunit which is responsible for many of the gabapentinoid side effects.
RESULTS: Mirogabalin\'s slower dissociation from the α2δ-1 compared with α2δ-2, and its higher potency may also impart an efficacy benefit over traditional gabapentinoids. These theoretical advantages of mirogabalin remain inconclusive in clinical practice, with mixed evidence regarding mirogabalin versus traditional gabapentinoids. Some studies suggest a reduced side effect profile yet, others fail to demonstrate significant differences. Regarding efficacy, mirogabalin may be superior to placebo for several neuropathic pain syndromes, but evidence of widespread benefit over traditional gabapentinoids is currently lacking.
CONCLUSIONS: Mirogabalin offers theoretical promise, but large, independent studies are required to further assess its performance versus traditional gabapentinoids.
RESULTS: Mirogabalin\'s slower dissociation from the α2δ-1 compared with α2δ-2, and its higher potency may also impart an efficacy benefit over traditional gabapentinoids. These theoretical advantages of mirogabalin remain inconclusive in clinical practice, with mixed evidence regarding mirogabalin versus traditional gabapentinoids. Some studies suggest a reduced side effect profile yet, others fail to demonstrate significant differences. Regarding efficacy, mirogabalin may be superior to placebo for several neuropathic pain syndromes, but evidence of widespread benefit over traditional gabapentinoids is currently lacking.
CONCLUSIONS: Mirogabalin offers theoretical promise, but large, independent studies are required to further assess its performance versus traditional gabapentinoids.
摘要：
目的：米罗加巴林是一种用于治疗神经病理性疼痛的新型加巴喷丁类药物。这篇综述的目的是讨论其使用的当前证据。加巴喷丁被广泛用于神经性疼痛。由于米罗加巴林对电压门控钙通道的α2δ-1亚基的特异性，因此与传统的加巴喷丁类化合物相比具有理论上的优势。从理论上讲，这种特异性可以通过使与α2δ-2亚基的结合最小化来减少药物不良反应，α2δ-2亚基是许多加巴喷丁类药物副作用的原因。
结果：与α2δ-2相比，米罗加巴林与α2δ-1的解离速度较慢，其更高的效力也可能比传统的加巴喷丁具有功效。米罗加巴林的这些理论优势在临床实践中仍然没有定论。关于米罗加巴林与传统加巴喷丁的混合证据。一些研究表明副作用有所减少，其他人没有表现出显著的差异。关于功效，对于几种神经性疼痛综合征，米罗加林可能优于安慰剂，但是目前缺乏比传统加巴喷丁类药物广泛获益的证据。
结论：米罗加巴林提供了理论上的希望，但是很大，需要进行独立研究以进一步评估其与传统加巴喷丁类药物的性能.
结果：与α2δ-2相比，米罗加巴林与α2δ-1的解离速度较慢，其更高的效力也可能比传统的加巴喷丁具有功效。米罗加巴林的这些理论优势在临床实践中仍然没有定论。关于米罗加巴林与传统加巴喷丁的混合证据。一些研究表明副作用有所减少，其他人没有表现出显著的差异。关于功效，对于几种神经性疼痛综合征，米罗加林可能优于安慰剂，但是目前缺乏比传统加巴喷丁类药物广泛获益的证据。
结论：米罗加巴林提供了理论上的希望，但是很大，需要进行独立研究以进一步评估其与传统加巴喷丁类药物的性能.
